Broadcast Date:
- Time:
As drug developers turn toward more targeted and mechanism-based approaches, understanding how therapeutics alter transcriptional activity is essential. For potential candidates that act on the epigenome or chromatin-associated proteins, traditional gene expression assays are not sufficient to fully uncover the mechanism of action (MOA) or predict patient response.
In this GEN webinar, Dave Lahr, PhD, Senior Director of Bioinformatics at Foghorn Therapeutics, discusses chromatin regulation and epigenetic mechanisms that shape transcriptional responses to drug treatment. During the webinar, you will learn how assays such as CUT&RUN (e.g. EpiCypher’s CUTANA™ CUT&RUN), ATAC-seq, and bisulfite sequencing map chromatin dynamics at high resolution, offering a more precise readout of MOA. He will share data from case studies of targeted protein degraders and enzyme inhibitors that demonstrate how epigenomic tools support MOA characterization and accelerate drug development.
A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.
Produced with support from:
